The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate · EFAVIRENZ 400 mg/1; LAMIVUDINE 300 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 · Tablet, Film Coated · Oral · Laurus Labs Limited
NDC 42385-0929-18 · 180 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 42385-0929-31) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$41.62per unit
middle half $35.67–$46.79 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $41.62
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 5 · prior auth 0% · step therapy 0% · qty limit 58%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Laurus Labs LimitedIndiaanalysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA213038
- TE code
- —
- Approval date
- May 14, 2020
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Laurus Labs Limited | EFAVIRENZ 400 mg/1; LAMIVUDINE 300 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Laurus Labs Limited | EFAVIRENZ 600 mg/1; LAMIVUDINE 300 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Viatris Specialty LLC | EFAVIRENZ 600 mg/1; LAMIVUDINE 300 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate — NDC 42385-0929-18," retrieved September 3, 2026, https://drugdashboards.com/drug/42385092918.
Free to cite with attribution — see how the data is put together.